10-Q: Vycor Medical Reports Q1 2025 Results: Revenue Up 30% but Losses Persist Amid Going Concern Uncertainty

Vycor Medical's Q1 2025 shows revenue growth of 30% year-over-year, but the company continues to face net losses and substantial doubt about its ability to continue as a going concern.

Summary

• Vycor Medical, Inc. reported its financial results for the first quarter of 2025.
• The company's revenue increased by 30% to $436,378, compared to $336,968 in the same period last year.
• Vycor Medical's revenue grew by 31%, while NovaVision's revenue decreased by 3%.
• The company experienced a net loss of $38,563 for the quarter, compared to a net loss of $30,608 in Q1 2024.
• The company's operating expenses increased to $371,340 from $309,494 in the prior year.
• The company's working capital deficiency was $4,052,879 as of March 31, 2025.
• The report raises substantial doubt about the company's ability to continue as a going concern due to recurring losses and a working capital deficiency.
• The company is exploring options for additional funding through debt or equity securities.
• The company's largest shareholder, Fountainhead, has provided working capital funding on an as-needed basis.

Sentiment

Score: 4

Explanation: While revenue growth is positive, the persistent losses, working capital deficiency, and going concern uncertainty weigh heavily on the sentiment. The potential need for a capital raise adds further concern.

Positives

• Vycor Medical's revenue increased by 30% year-over-year.
• Vycor Medical division revenue increased 31% due to growth in both US and international markets.
• Gross margin for Vycor Medical was 82% for the three months ended March 31, 2025.
• The company is actively pursuing strategies to increase revenue growth, including market penetration and new product development.
• Maxim Group LLC has been engaged to assist in the company's strategy to accelerate growth through strategic acquisitions and partnerships.

Negatives

• The company experienced a net loss of $38,563 for the quarter.
• The company's working capital deficiency was $4,052,879 as of March 31, 2025.
• The report indicates substantial doubt about the company's ability to continue as a going concern.
• NovaVision revenue decreased slightly by 3%.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and a working capital deficiency.
• The company may not have sufficient cash to meet its needs through May 31, 2026, without additional funding.
• There is no guarantee that Fountainhead will continue to provide working capital funding.
• The company may have to delay or curtail development or commercialization of products, or cease some of its operations if adequate funds are not available.
• The imposition of retaliatory tariffs by countries to which the company exports could negatively impact international revenues.
• The company's lack of a functioning audit committee with independent members results in ineffective oversight in the establishment and monitoring of required internal controls and procedures.

Future Outlook

The company is executing a plan to achieve revenue growth and is considering seeking additional equity or debt funding. Management is also open to a broad range of alternatives for NovaVision as a whole, which could comprise distribution and marketing partnerships, licensing, merger or sale.

Management Comments

• Management is open to a broad range of alternatives for NovaVision as a whole, which could comprise distribution and marketing partnerships, licensing, merger or sale.
• The Company is continuing to execute on a plan to achieve revenue growth.

Industry Context

The company operates in the medical device industry, with a focus on neurosurgery and vision rehabilitation therapies. The company's strategy includes increasing market penetration, new product development, and partnerships to leverage its existing distribution network. The company is also exploring strategic acquisitions to accelerate growth.

Comparison to Industry Standards

• It is difficult to compare Vycor Medical directly to industry standards due to its small size and specific focus within the neurosurgery and vision rehabilitation markets.
• Larger medical device companies like Medtronic, Johnson & Johnson, and Stryker have significantly higher revenues and resources, allowing for greater investment in R&D and marketing.
• Smaller companies in the medical device sector often rely on niche markets and strategic partnerships to compete.
• Vycor's focus on minimally invasive solutions aligns with a broader trend in the medical device industry towards less invasive procedures.
• NovaVision's vision rehabilitation therapies compete with other non-invasive therapies and traditional vision correction methods.

Corporate Governance

Legal Proceedings

• The company is subject from time to time to litigation, claims and suits arising in the ordinary course of business.
• As of May 15, 2025, the company was not a party to any material litigation, claim or suit whose outcome could have a material effect on its financial statements.

Related Party Transactions

• Peter Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at March 31, 2025, 60.9 % of the Company's Common Stock and 69.7 % of the Company's Series D Preferred Stock.
• Peter Zachariou owns 0.15 % of the Company's Common Stock and 25.7 % of the Company's Series D Preferred Stock.
• Adrian Liddell, Chairman is a consultant to Fountainhead.
• During each of the three months ended March 31, 2025 and 2024, the Company accrued an aggregate of $ 162,185 of Preferred D Stock dividends, of which $ 113,019 was regarding Fountainhead and $ 41,693 was regarding Peter Zachariou.
• During the three months ended March 31, 2025 and 2024 the Company accrued interest on related party loans of $ 12,570 and $ 12,031 , respectively.

Stakeholder Impact

• Shareholders face uncertainty due to the company's going concern status and potential need for additional funding.
• Employees may be affected by potential delays or curtailment of development or commercialization of products, or cessation of operations.
• Customers may be impacted by potential disruptions in product availability or service.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company will continue to execute on its plan to achieve revenue growth.
• The company may consider seeking additional equity or debt funding.
• The company will continue to monitor the impact of trade tariffs on its international revenues.
• The company will work to resolve the material weakness in internal controls related to the lack of a functioning audit committee.

Key Dates

Keywords

Vycor Medical, NovaVision, revenue, net loss, financial results, going concern, medical devices, neurosurgery, rehabilitation therapies, VBAS, working capital, Fountainhead, Maxim Group